{
  "source": "PA-Notification-Inrebic.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1294-6\nProgram Prior Authorization/Notification\nMedication Inrebic® (fedratinib)\nP&T Approval Date 10/2019, 10/2020, 10/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nInrebic (fedratinib) is a kinase inhibitor indicated for the treatment of adult patients with\nintermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential\nthrombocythemia) myelofibrosis (MF).\nThe National Cancer Comprehensive Network (NCCN) also recommends Inrebic for the\ntreatment of myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangement.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Inrebic will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Myelofibrosis\n1. Initial Authorization\na. Inrebic will be approved based on the following diagnoses:\n(1) Diagnosis of intermediate-2 or high-risk primary or secondary (post-\npolycythemia vera or post-essential thrombocythemia) myelofibrosis\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\na. Inrebic will be approved based on the following criterion:\n(1) Documentation that patient has evidence of symptom improvement or\nreduction in spleen volume while on Inrebic\nAuthorization will be issued for 12 months.\nC. Myeloid/Lymphoid Neoplasms\n1. Initial Authorization\na. Inrebic will be approved base",
    "f symptom improvement or\nreduction in spleen volume while on Inrebic\nAuthorization will be issued for 12 months.\nC. Myeloid/Lymphoid Neoplasms\n1. Initial Authorization\na. Inrebic will be approved based on both of the following:\n(1) Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with\neosinophilia\n-AND-\n(2) Patient has a JAK2 rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Inrebic will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Inrebic therapy.\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Inrebic [package insert]. Summit, NJ: Celgene Corporation. July 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/ Accessed September 4, 2024\nProgram Prior Authorization/Notification – Inrebic® (fedratinib)\nChange Control\n10/2019 New program.\n10/2020 Annual review. Updated background and coverage criteria to include\nNCCN recommended use in myeloid/lymphoid neoplasms. Updated\nreferences.\n10/2021 Annual r",
    "\nChange Control\n10/2019 New program.\n10/2020 Annual review. Updated background and coverage criteria to include\nNCCN recommended use in myeloid/lymphoid neoplasms. Updated\nreferences.\n10/2021 Annual review with no change to clinical coverage criteria.\n10/2022 Annual review. Updated myelofibrosis criteria to labeled indication.\nUpdated references. Added state mandate footnote.\n10/2023 Annual review with no change to clinical coverage criteria. Updated\nreferences.\n10/2024 Annual review with no change to clinical coverage criteria. Updated\nreferences.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}